The RegMed universe is in … dire need of a catalyst to halt these days of … flat lines, depreciation and red ink … with …very little market action …. But, NO real movement… The Nasdaq Composite had its bulkiest advance in over 3 months; yet volume, an objective measure of demand strength, left something to be desired, as NASDAQ turnover came in 29% below normal. Lately … large moves are … just signs of volitility… (short coverings?) … that won’t continue …
From an intermediate-term standpoint, the trend remains … down, and Monday and Tuesday does nothing to change this fact. What would change it … is some tangible evidence that institutions have enough confidence in this market to put money to work with conviction. The EU situation remains as fraught with risk as it did last yesterday, the day before … the week before … last month and the month before.
Closing Bell: The NASDAQ closed DOWN -11.33 (-0.47%) to 2,516. The Dow closed UP +33 (+0.28%) to 11,556.
Who’s up … at the close and any … whys: Athersys (NASDAQ:ATHX)+$0.03 <+ 2.42%> to $1.27; Geron (NASDAQ:GERN) +$0.01 <+0.65%> to $1.55; ImmunoCellular (OTC BB: IMUC) +$0.04 <+2.94%> to $1.40; Neuralstem (AMEX: CUR) +$0.01 <+0.93%> to $1.09 .